Transporters and Drug-Metabolizing Enzymes in Drug Toxicity. Albert P. Li
Frankenberg T, Rao A, Chen F, Haywood J, Shneider BL, Dawson PA. Regulation of the mouse organic solute transporter alpha‐beta, Ostalpha‐Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol 2006; 290(5):G912–22.
136 136 Landrier JF, Eloranta JJ, Vavricka SR, Kullak‐Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter‐alpha and ‐beta genes. Am J Physiol Gastrointest Liver Physiol 2006; 290(3):G476–85.
137 137 Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148(4):751–61 e8.
138 138 Ali AH, Lindor KD. Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opin Pharmacother 2016; 17 (13):1809–15.
139 139 Erlinger S. Obeticholic acid in primary biliary cholangitis. Clin Res Hepatol Gastroenterol 2017; 41(1):3–5.
140 140 Nevens F, Lindor KD, Jones DE. Obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (20):e41.
141 141 Spacek LA, Solga SF. Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016; 375 (20):e41.
142 142van Golen RF. Obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (20):e41.
143 143 Quigley G, Al Ani M, Nadir A. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation. Dig Dis Sci 2018; 63(2):529–32.
144 144 Chiang JY. Bile acid metabolism and signaling. Compr Physiol 2013; 3(3):1191–212.
145 145 Li T, Chiang JY. Nuclear receptors in bile acid metabolism. Drug Metab Rev 2013; 45(1):145–55.
146 146 Li T, Chiang JY. Bile acid signaling in liver metabolism and diseases. J Lipids 2012; 2012:754067.
147 147 Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther 2017; 34(9):2120–38.
148 148 Zhang Y, Jackson JP, St Claire RL, 3rd, Freeman K, Brouwer KR, Edwards JE. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes. Pharmacol Res Perspect. 2017; 5(4), e00329.
149 149 Guo C, LaCerte C, Edwards JE, Brouwer KR, Brouwer KLR. Farnesoid X receptor agonists obeticholic acid and chenodeoxycholic acid increase bile acid efflux in sandwich‐cultured human hepatocytes: functional evidence and mechanisms. J Pharmacol Exp Ther 2018; 365(2):413–21.
150 150 Kahler CM, Graziadei I, Vogelsinger H, Desole S, Cima K, Vogel W. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr 2011; 123 (7–8):248–52.
151 151 Scott LJ. Sitaxentan: in pulmonary arterial hypertension. Drugs 2007; 67(5):761–70; discussion 71‐2.
152 152 Gholam P, Sehr T, Enk A, Hartmann M. Successful treatment of systemic‐sclerosis‐related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). Dermatology 2009; 219(2):171–3.
153 153 Zhang J, Kong W, Wang C. Mechanism of plasma endothelin‐1 level elevation and its relation with pulmonary hypertension in chronic cor pulmonale. Zhonghua Nei Ke Za Zhi 1996; 35(2):110–3.
154 154 Galie N, Hoeper MM, Simon J, Gibbs R, Simonneau G, Task Force for the D, et al. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Heart J 2011; 32(4):386–7.
155 155 Lavelle A, Sugrue R, Lawler G, Mulligan N, Kelleher B, Murphy DM, et al. Sitaxentan‐induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009; 34(3):770–1.
156 156 Lee WT, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, Peacock AJ. Sitaxentan‐related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011; 37(2):472–4.
157 157 Hoeper MM, Olsson KM, Schneider A, Golpon H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009; 33(6):1518–9.
158 158 Owen K, Cross DM, Derzi M, Horsley E, Stavros FL. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin(R)), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Regul Toxicol Pharmacol 2012; 64(1):95–103.
159 159 Erve JC, Gauby S, Maynard JW, Jr., Svensson MA, Tonn G, Quinn KP. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol 2013; 26(6):926–36.
160 160 Whitley RJ. Sorivudine: a potent inhibitor of varicella zoster virus replication. Adv Exp Med Biol 1996; 394:41–4.
161 161 Whitley RJ. Sorivudine: a promising drug for the treatment of varicella‐zoster virus infection. Neurology 1995; 45 (12 Suppl 8):S73–5.
162 162 Burdge DR, Voigt R, Lindley JI, Gage L, Sacks SL. Sorivudine (BV‐ara‐U) for the treatment of complicated refractory varicella zoster virus infection in HIV‐infected patients. AIDS 1995; 9(7):810–2.
163 163 Pinnolis MK, Foxworthy D, Kemp B. Treatment of progressive outer retinal necrosis with sorivudine. Am J Ophthalmol 1995; 119(4):516–7.
164 164 Wunderli W, Miner R, Wintsch J, von Gunten S, Hirsch HH, Hirschel B. Outer retinal necrosis due to a strain of varicella‐zoster virus resistant to acyclovir, ganciclovir, and sorivudine. Clin Infect Dis 1996; 22(5):864–5.
165 165 Bodsworth NJ, Boag F, Burdge D, Genereux M, Borleffs JC, Evans BA, et al. Evaluation of sorivudine (BV‐araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus‐infected adults. The Multinational Sorivudine Study Group. J Infect Dis 1997; 176(1):103–11.
166 166 Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5‐fluorouracil prodrugs. Drug Metab Dispos 1997; 25(5):270–3.
167 167 Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5‐fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287(2):791–9.
168 168 Diasio RB. Sorivudine and 5‐fluorouracil; a clinically significant drug‐drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998; 46(1):1–4.
169 169 Dawson RM. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett 1990; 118(1):85–7.
170 170 Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A. Long‐term hepatotoxicity of tacrine. Lancet 1989; 1(8640):729.
171 171 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13):992–8.
172 172 Fredj G, Dietlin F, Barbier G, Jasmin C, Bonhomme L, Esctein S, et al. Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS. Therapie 1992; 47(3):245–7.
173 173 Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996; 10(2):156–7.
174 174 Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein‐reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46(1):13–20.
175 175 Hendrickson HP, Scott DO, Lunte CE. Identification of 9‐hydroxylamine‐1,2,3,4‐tetrahydroacridine as a hepatic microsomal metabolite of tacrine by high‐performance liquid chromatography and electrochemistry. J Chromatogr 1989; 487(2):401–8.
176 176 Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck‐Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine